AbbVie Inc. (NYSE:ABBV) Shares Bought by Silvia Mccoll Wealth Management LLC

Silvia Mccoll Wealth Management LLC boosted its position in shares of AbbVie Inc. (NYSE:ABBV) by 2.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,120 shares of the company’s stock after purchasing an additional 66 shares during the period. Silvia Mccoll Wealth Management LLC’s holdings in AbbVie were worth $527,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ABBV. Claro Advisors LLC grew its holdings in AbbVie by 1.5% during the 1st quarter. Claro Advisors LLC now owns 23,962 shares of the company’s stock worth $4,363,000 after acquiring an additional 363 shares in the last quarter. Talbot Financial LLC lifted its position in shares of AbbVie by 1.1% in the 1st quarter. Talbot Financial LLC now owns 89,494 shares of the company’s stock worth $16,297,000 after buying an additional 954 shares during the last quarter. CCG Wealth Management LLC bought a new position in shares of AbbVie in the 1st quarter worth about $264,000. Miracle Mile Advisors LLC lifted its position in shares of AbbVie by 6.6% in the 1st quarter. Miracle Mile Advisors LLC now owns 29,243 shares of the company’s stock worth $5,325,000 after buying an additional 1,801 shares during the last quarter. Finally, Kowal Investment Group LLC lifted its position in shares of AbbVie by 13.2% in the 1st quarter. Kowal Investment Group LLC now owns 14,335 shares of the company’s stock worth $2,610,000 after buying an additional 1,671 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on ABBV. BMO Capital Markets reduced their price target on shares of AbbVie from $195.00 to $180.00 and set an “outperform” rating on the stock in a research report on Monday, April 29th. Guggenheim raised their price target on shares of AbbVie from $188.00 to $190.00 and gave the stock a “buy” rating in a research report on Friday, March 22nd. Piper Sandler raised their price target on shares of AbbVie from $185.00 to $190.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 18th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research report on Wednesday, June 5th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $200.00 price objective on shares of AbbVie in a research report on Thursday, June 20th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $179.64.

AbbVie Trading Down 0.7 %

Shares of NYSE:ABBV traded down $1.15 during mid-day trading on Monday, reaching $170.37. The stock had a trading volume of 5,194,624 shares, compared to its average volume of 5,670,859. The firm has a market cap of $300.85 billion, a PE ratio of 50.56, a price-to-earnings-growth ratio of 2.19 and a beta of 0.64. The firm has a 50 day simple moving average of $164.60 and a two-hundred day simple moving average of $167.63. The company has a current ratio of 0.94, a quick ratio of 0.83 and a debt-to-equity ratio of 7.93. AbbVie Inc. has a twelve month low of $132.70 and a twelve month high of $182.89.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, May 3rd. The company reported $2.31 earnings per share for the quarter, topping analysts’ consensus estimates of $2.26 by $0.05. AbbVie had a net margin of 11.02% and a return on equity of 179.47%. The business had revenue of $12.31 billion for the quarter, compared to the consensus estimate of $11.93 billion. During the same period in the previous year, the company earned $2.46 earnings per share. The firm’s revenue for the quarter was up .7% on a year-over-year basis. On average, research analysts predict that AbbVie Inc. will post 11.27 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, August 15th. Stockholders of record on Monday, July 15th will be issued a $1.55 dividend. The ex-dividend date is Monday, July 15th. This represents a $6.20 dividend on an annualized basis and a dividend yield of 3.64%. AbbVie’s dividend payout ratio (DPR) is currently 183.98%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.